Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.30 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19784991 | 0.90 | GPR119 (0.33) | ELANEGPR119MAP4K4HDAC1SCN9A | |
| SCHEMBL21245396 | 0.85 | — | — | |
| SCHEMBL19785150 | 0.84 | GPR119 (0.35) | ELANEGPR119MAP4K4HDAC1SCN9A | |
| SCHEMBL19784864 | 0.84 | GPR119 (0.33) | ELANEGPR119MAP4K4HDAC1 | |
| SCHEMBL19784863 | 0.84 | ELANE (0.32) | ELANEGPR119MAP4K4HDAC1SCN9A | |
| SCHEMBL19785132 | 0.83 | GPR119 (0.31) | GPR119MAP4K4 | |
| SCHEMBL19784995 | 0.83 | GPR119 (0.32) | ELANEGPR119MAP4K4HDAC1SCN9A | |
| SCHEMBL19784844 | 0.83 | GPR119 (0.33) | ELANEGPR119MAP4K4HDAC1SETD7 | |
| SCHEMBL19785002 | 0.82 | GPR119 (0.32) | ELANEGPR119MAP4K4HDAC1 | |
| SCHEMBL19784986 | 0.81 | GPR119 (0.32) | ELANEGPR119MAP4K4HDAC1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476668-B | 6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazines and 6, 7-dihydro-4H-triazolo [1,5-a ] pyrazines for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | HOFFMANN LA ROCHE INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3484886-B1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-20190248792-A1 | NOVEL PYRAZOLOPYRAZINE AND TRIAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2018011163-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248792-A1 | NOVEL PYRAZOLOPYRAZINE AND TRIAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | CYP3A5, RRP15, HAVCR2 | ELANE 3548/4885GPR119 766/4885MAP4K4 690/4885 |
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | CYP3A5, RRP15, QDPR | ELANE 3718/4885GPR119 1086/4885MAP4K4 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.